We would like to ensure that you are still receiving content that you find useful – please confirm that you would like to continue to receive ILO newsletters.
07 March 2018
On December 11 2017 Health Canada announced a guidance document clarifying the requirements for drug submissions and applications to be processed under the administrative pathway. The administrative pathway will be available, with some restrictions, for:
Any deviations from a previously approved product will be unacceptable under the administrative pathway.
This guidance replaces the Changes in Manufacturer's Name and/or Product Name Policy and will be effective from March 1 2018. For application of the Patented Medicines (Notice of Compliance) Regulations, the guidance refers to the Guidance Document: Patented Medicines (Notice of Compliance) Regulations.
For further information on this topic please contact Brandon Heard at Smart & Biggar/Fetherstonhaugh by telephone (+1 416 593 5514) or email (email@example.com). The Smart & Biggar/Fetherstonhaugh website can be accessed at www.smart-biggar.ca.
The materials contained on this website are for general information purposes only and are subject to the disclaimer.
ILO is a premium online legal update service for major companies and law firms worldwide. In-house corporate counsel and other users of legal services, as well as law firm partners, qualify for a free subscription.